Inhibition of LSD 1 sensitizes glioblastoma cells to histone deacetylase inhibitors

Departments of Pediatrics Research (M.M.S., C.A.M., J.C.), Pathology (K.P.B., K.A.), and Biochemistry and Molecular Biology (W-W.T., M.C.B.) and The Center for Cancer Epigenetics (M.M.S., C.A.M., W-W.T., K.A., M.C.B., J.C.), The University of Texas MD Anderson Cancer Center, and The University of Texas at Houston Health Science Center Graduate School of Biomedical Sciences (C.A.M., M.C.B., J.C.), Houston, Texas

[1]  Min Gyu Lee,et al.  Functional Interplay between Histone Demethylase and Deacetylase Enzymes , 2006, Molecular and Cellular Biology.

[2]  Patrick G. Shaw,et al.  Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells , 2012, Breast Cancer Research and Treatment.

[3]  M. Dokmanovic,et al.  Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.

[4]  Makoto Hasegawa,et al.  Identification of cell-active lysine specific demethylase 1-selective inhibitors. , 2009, Journal of the American Chemical Society.

[5]  John A Latham,et al.  Cross-regulation of histone modifications , 2007, Nature Structural &Molecular Biology.

[6]  A. Zelenetz,et al.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[8]  R. Versteeg,et al.  Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. , 2009, Cancer research.

[9]  Min Gyu Lee,et al.  Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. , 2006, Chemistry & biology.

[10]  G. Giaccone,et al.  Histone deacetylase inhibitors in cancer therapy , 2008, Current opinion in oncology.

[11]  P. Cole,et al.  Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. , 2010, Journal of the American Chemical Society.

[12]  Antoine H. F. M. Peters,et al.  LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription , 2005, Nature.

[13]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[14]  K. Krishnan.  Revisiting monoamine oxidase inhibitors. , 2007, The Journal of clinical psychiatry.

[15]  Z. Cao,et al.  CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo , 2006, Molecular Cancer Therapeutics.

[16]  Caterina Giannini,et al.  Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Aldape,et al.  Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. , 2001, Cancer research.

[18]  Jerry L. Workman,et al.  Crosstalk among Histone Modifications , 2008, Cell.

[19]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[20]  P. Marks,et al.  Histone deacetylase inhibitors: discovery and development as anticancer agents , 2005, Expert opinion on investigational drugs.

[21]  J. Byrd,et al.  Histone Deacetylase Inhibitors Stimulate Histone H3 Lysine 4 Methylation in Part Via Transcriptional Repression of Histone H3 Lysine 4 Demethylases , 2011, Molecular Pharmacology.

[22]  J. Costello,et al.  Molecular epigenetics and genetics in neuro-oncology , 2009, Neurotherapeutics.

[23]  D. M. Schmidt,et al.  trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. , 2007, Biochemistry.

[24]  Paul Dent,et al.  The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. , 2003, Blood.

[25]  P. Cole,et al.  A mechanism-based inactivator for histone demethylase LSD1. , 2006, Journal of the American Chemical Society.

[26]  Min Gyu Lee,et al.  p53 is regulated by the lysine demethylase LSD1 , 2007, Nature.

[27]  M. Keating,et al.  Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. , 2009, Blood.

[28]  S. Baylin,et al.  Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes , 2007, Proceedings of the National Academy of Sciences.

[29]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[30]  A. Mai,et al.  Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. , 2010, Journal of the American Chemical Society.

[31]  W. Forrester,et al.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Sarkaria,et al.  Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. , 2008, Neuro-oncology.

[33]  Ccr Focus.  Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications , 2009 .

[34]  S. Payne,et al.  Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. , 2005, Cancer research.

[35]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[36]  Paul Talalay,et al.  Analysis of combined drug effects: a new look at a very old problem , 1983 .

[37]  P. Black,et al.  Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model , 2007, Journal of Neuro-Oncology.

[38]  M. Machius,et al.  Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. , 2007, Biochemistry.

[39]  Yang Shi,et al.  Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1 , 2004, Cell.

[40]  S. Tucker,et al.  Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci , 2006, Molecular Cancer Therapeutics.

[41]  A. Carpentier.  Neuro-oncology: the growing role of chemotherapy in glioma , 2005, The Lancet Neurology.

[42]  M. Munsell,et al.  NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. , 2007, Blood.

[43]  Yang Shi,et al.  p53-Targeted LSD1 Functions in Repression of Chromatin Structure and Transcription In Vivo , 2008, Molecular and Cellular Biology.

[44]  G. Fuller,et al.  An implantable guide-screw system for brain tumor studies in small animals. , 2000, Journal of neurosurgery.